

## CZECH REPUBLIC

### Recent and planned developments in pharmaceutical policies 2016

#### Special topic: Out-of pocket payments

D E V E L O P M E N T S	<b>CHANGES IN PRICING</b>	<b>CHANGES IN REIMBURSEMENT</b>
	<ul style="list-style-type: none"> <li>• <u>No relevant system changes in 2016</u></li> <li>• <u>Discussion</u> about possibility of common international approach considering price negotiations.</li> <li>• <u>Discussion</u> about generic/biosimilar price link modification - raise of the obligatory price decrease for generic product from 32 % to 40 % and for biosimilar product from 15 % to 30 %.</li> </ul>	<ul style="list-style-type: none"> <li>• <u>No relevant system changes in 2016</u></li> <li>• Ongoing 2<sup>nd</sup> and 3<sup>rd</sup> waves of complex reimbursement reviews</li> <li>• Reimbursement of generic/biosimilar is correlating with its price. The change of price decrease would reflect also to reimbursement.</li> </ul>
	<b>OTHER CHANGES</b>	
	<ul style="list-style-type: none"> <li>• Planned law regulation of re-export. Selected medicinal products will be published in bulletin and they could not be exported. Sanctions up to 20 million CZK and prohibition of activity up to 2 years.</li> </ul>	
S P E C I A L T O P I C	<b>OUT-OF POCKET PAYMENTS</b>	
	<p><u>Out-patient sector</u></p> <ul style="list-style-type: none"> <li>• Maximal price and reimbursement price of the pharmaceutical product are stated in separate processes and set as nominal values.             <ul style="list-style-type: none"> <li>◦ Both processes are primarily based on ERP.</li> </ul> </li> <li>• The difference between reimbursement price and pharmacy retail price is the co-payment for a patient.</li> <li>• For reimbursement price the system of reference groups is applied.             <ul style="list-style-type: none"> <li>◦ Groups of pharmaceuticals which have similar effectiveness, safety profile and clinical use and are considered to be therapeutically interchangeable.</li> <li>◦ All pharmaceuticals within the same reference group have the same reimbursement price for usual daily dose.</li> </ul> </li> <li>• Different list of groups of pharmaceuticals in Annex No. 2 of the Act No. 48/1997 Coll., on Public Health Insurance             <ul style="list-style-type: none"> <li>◦ At least one fully reimbursed medicine must be in each group</li> </ul> </li> <li>• OTC medicines that are not prescribed are to be fully paid by the patient             <ul style="list-style-type: none"> <li>◦ Only small group of OTC has reimbursement.</li> </ul> </li> <li>• Annual co-payment ceilings are established.             <ul style="list-style-type: none"> <li>◦ 2500 CZK for patients under 18 years and above 65 years old</li> <li>◦ 5000 CZK for other patient</li> <li>◦ Only co-payments for the cheapest medicinal product from the group are counted into this amount (the lowest possible co-payment for a patient)</li> <li>◦ The ceilings are proposed to change.                 <ul style="list-style-type: none"> <li>▪ 1000 CZK for patients under 18 years and above 65 years.</li> <li>▪ 500 CZK for patients above 70 years</li> </ul> </li> </ul> </li> </ul> <p><u>In-patient sector</u></p> <ul style="list-style-type: none"> <li>• Patients do not have to provide extra payments for medicines they receive during their in-patient stay.</li> </ul>	